[rank_math_breadcrumb]

Politics

3 Penny Stocks With Market Caps Larger Than US$300M To Watch

Updated: 23-10-2024, 04.02 AM

As global markets show varied performances, with small-cap indices like the Russell 2000 and S&P MidCap 400 outperforming their larger counterparts, investors are keenly observing opportunities across different market segments. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as potential investment vehicles for those seeking value in smaller or newer companies. This article explores three penny stocks that stand out due to their financial robustness and potential for long-term growth amidst current market dynamics.

Name

Share Price

Market Cap

Financial Health Rating

Tristel (AIM:TSTL)

£3.95

£184.64M

★★★★★★

BP Plastics Holding Bhd (KLSE:BPPLAS)

MYR1.20

MYR337.78M

★★★★★★

DXN Holdings Bhd (KLSE:DXN)

MYR0.60

MYR2.96B

★★★★★★

Rexit Berhad (KLSE:REXIT)

MYR0.74

MYR128.18M

★★★★★★

Lever Style (SEHK:1346)

HK$0.77

HK$488.79M

★★★★★★

Zhejiang Giuseppe Garment (SZSE:002687)

CN¥4.23

CN¥2.07B

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.905

MYR300.41M

★★★★★★

Hume Cement Industries Berhad (KLSE:HUMEIND)

MYR3.58

MYR2.59B

★★★★★☆

Embark Early Education (ASX:EVO)

A$0.805

A$128.44M

★★★★☆☆

Next 15 Group (AIM:NFG)

£4.355

£407.27M

★★★★☆☆

Click here to see the full list of 5,783 stocks from our Penny Stocks screener.

Let’s dive into some prime choices out of the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Abbisko Cayman Limited is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule oncology therapies in Mainland China, with a market cap of HK$2.43 billion.

Operations: The company’s revenue is derived from the development of innovative medicines, amounting to CN¥497.27 million.

Market Cap: HK$2.43B

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, has shown significant revenue growth, reporting CN¥497.27 million for the first half of 2024 compared to CN¥19.06 million the previous year. Despite being unprofitable and forecasted to remain so for at least three years, it has reduced losses by 17.5% annually over five years. The company benefits from a seasoned management team and board with average tenures of 3.7 and 3.3 years respectively, no debt burden, and sufficient cash runway exceeding three years under current free cash flow conditions. Recently added to the S&P Global BMI Index, Abbisko’s stock trades significantly below its estimated fair value.

SEHK:2256 Debt to Equity History and Analysis as at Oct 2024
SEHK:2256 Debt to Equity History and Analysis as at Oct 2024

Simply Wall St Financial Health Rating: ★★★★★★

Leave a Comment

Design by proseoblogger